A Comparison of the Outcomes of Distal Fingertip Amputations Treated With Either Artificial (Xeroform) or Biological Dressings

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03968835

Enrollment

Registered

2019-05-30

Start date

2018-12-24

Completion date

2021-05-31

Last updated

2020-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation, Traumatic, Finger Injuries

Brief summary

This is a prospective study looking to evaluate whether the treatment outcomes for patients who sustain a distal fingertip amputation are improved or no different when using biological dressings versus artificial dressings.

Interventions

OTHERBacitracin

For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.

OTHERSkin Graft

For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 100 Years

Healthy volunteers

Inclusion criteria

* All individuals presenting at Bellevue Hospital for evaluation and treatment of a finger amputation distal to the germinal matrix that present along with the amputated distal fingertip unit.

Exclusion criteria

* replantation candidate, incomplete distal finger-tip amputation

Design outcomes

Primary

Measure	Time frame
Time to complete healing up to 3 Months	3 months
Percentage of graft viability (for biological dressing only)	1 week

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026